Introduction
Infective endocarditis has been said to cause about 200 deaths each year in England and Wales, a mortality rate of approximately 30%, although the true incidence is probably higher (Working Party, 1985) . Early recognition and effective antimicrobial treatment are essential to success. Glycopeptides are used in patients allergic to penicillins or if the pathogen is resistant to first line agents, but failures have been reported, with vancomycin, particularly when used as monotherapy (Small & Chambers, 1990) . Vancomycin is associated with rash, red man syndrome and, when used in combination with aminoglycosides, nephrotoxicity (Sorrell & Collignon, 1985; Rybak et al., 1990) .
Teicoplanin is another glycopeptide antibiotic with activity against most endocarditis, follow-up had to be at least for 3-4 months and for prosthetic valve endocarditis 5-7 months. Teicoplanin assays were requested at the discretion of individual hospitals in this study and were performed at University College Hospital. An agar diffusion method was used (Patton et al., 1987) with Bacillus subtilis NCTC 10400, ATCC 6633, (Difco, Michigan, USA) as indicator organism. In the presence of /?-lactam antibiotics, samples were treated with /Mactamase (Genzyme Biochemicals, Suffolk). A multi-resistant Staphylococcus aureus was employed as indicator organism when antibiotics other than /Mactams were given concomitantly with teicoplanin. The limit of sensitivity using B. subtilis was 0.5 mg/L and using 5. aureus was 1.0 mg/L. The coefficients of variation at the high (40 mg/L), median (8 mg/L) and lower end (1 mg/L) of sensitivity were 5.38%, 5.84% and 7.82% respectively.
For normally distributed variables the 95% confidence interval (CI) for the mean or for the difference in the means was calculated (Altman & Gardner, 1989) . Proportions were tested by the chi-square test with Yates' correction (Armitage & Berry, 1987) . The Student t test was used to test significance of differences (Armitage & Berry, 1987) . To distinguish non-parametric variables, the Mann Whitney U test was used.
Results
There were 58 episodes of native valve endocarditis and 46 of prosthetic valve endocarditis. One man and two women had two episodes of infection treated with teicoplanin. The male:female ratio of patients with native valve infection was not significantly different from that of patients with prosthetic infection (49:9 vs 33:13, NS X 2 test). Patients with prosthetic infections were significantly older than those with native infections (mean 59 years, range 30-77, vs 46 years, range 0.5-85, 95% CI for difference 6.5-20 years, t = 3.9, P = 0.0002). The mean weight was 64.4 kg with a range of 3-101 kg (95% CI for mean 61.5-67.2 kg).
The aortic valve was the most frequent site of infection for both native and prosthetic valves (Table I) . For 46 patients with prosthetic valves, the median interval from surgery to admission for endocarditis was 1.4 years with a maximum of 29 years. Thirteen (28%) patients developed endocarditis within two months of surgery, three patients before discharge from hospital. The delay from the onset of symptoms to admission in all patients was a median of 21 days (range 1-240 days) ( Table II) . The duration of admission for native valve endocarditis was a median of 54 days (1-177 days) and for prosthetic endocarditis 50 days (range 6-139 days).
A total of 85 (82%) patients had received antibiotics before starting treatment with teicoplanin. Eight patients had received one antibiotic, 21 two antibiotics, 30 three antibiotics, and 26 four or more antibiotics. Twenty-five different agents were used with a median course length of 8 days (range 0-85). The most popular choices were benzyl penicillin (55%), gentamicin (78%), flucloxacillin (38%), vancomycin (24%), cefuroxime (18%), erythromycin (15%), and fusidic acid (13%). The most common reasons for change were failure of treatment (e.g. persistent fever, emboli, development of abscess) (52%) or recurrence of fever after an initial response (12%). Failure or recurrence occurred in 34 (59%) of 58 native infections and 17 (37%) of 46 prosthetic infections. In 17 (20%) of the 104 cases, the pathogen was known or suspected to be resistant to the antibiotics used. In four (5%), the antibiotics had been used for other infections. Adverse reactions were another common cause for change including rash (19%), renal failure (11%), neutropenia (4%), difficulty in maintaining gentamicin or vancomycin concentrations within therapeutic range (4%) and red man syndrome (2%). Of the 20 changed from vancomycin, the usual reasons were failure of treatment (ten patients), adverse events (three patients), and renal failure (five patients).
A loading regimen had been used in 78 (75%) patients given teicoplanin, the most common regimen being 400 mg (6 mg/kg) at 12 h intervals for three doses. Initial doses ranged between 45 mg and 2.4 g and the number of doses between 1 and 18 (median 3), usually 12-hourly. The median initial dose was 6.3 mg/kg (range 1.5-30). The maintenance regimen was usually 400 mg every 24 h (range 30 mg to 2.4 g/day). The initial dosage was given for a median of 14 days (range 0-80), the course being curtailed in some by surgery, treatment with other antibiotics or death. In 28 patients, the dosage of teicoplanin was then changed (median 400 mg/day, range 90mg-1.6g, 12-72 h) because of failure to improve (six cases), renal failure (15 cases), reduced susceptibility of the pathogen (one case), nausea (one case) and low serum concentrations (one case). The second regimen lasted a median of 14 days (2-58 days). Nine patients received a third dosage (4-23 days) and four a fourth dosage (3-37 days) for similar reasons, each lasting a median of nine days. The total length of treatment with teicoplanin was a median of 28 days, range 3-83 days. Twelve patients received part of their course at home. There was no significant difference in the dosage used for prosthetic or native infections. Although the median daily dose in each case was 400 mg, a significantly higher dose was used in patients with disease caused by S. aureus (range 200-2400 mg/day) than in streptococcal disease (range 80-800 mg/day) (Mann Whitney P = 0.02). Only two patients were intravenous drug abusers.
Concurrent antibiotics were given in 92 (90%) patients. Eighteen different agents were used, the most common being gentamicin (49%), rifampicin (45%) and fusidic acid (16%). A single concurrent antibiotic was given in 52% of the 104 cases, usually gentamicin (24 cases) or rifampicin (22 cases). Two concurrent antibiotics were given in 31 (30%) cases, the most common combination being gentamicin and rifampicin (four cases). In six cases, three or more other antibiotics were given during the course of treatment. The choice of antibiotic was similar for prosthetic and native valve infections. Gentamicin was usually given only for the first 14 days of treatment whereas rifampicin or fusidic acid were used throughout the course of teicoplanin (Table III) . Other antibiotics were given for short periods, often to treat intercurrent infection or as surgical prophylaxis.
Antibiotics were given after the course of teicoplanin was completed in 47 (45%) patients, a single agent being given in 20 patients, two in 18 patients, and three or more in nine patients (Table IV) . In 12 patients, the clinician wanted to continue with oral treatment despite resolution of signs of disease on teicoplanin. Ten patients had adverse reactions to teicoplanin, 11 had failed treatment, in four the organism was resistant or not killed in vitro and in two it was found to be susceptible to an oral agent. Five had other infections and three had to be discharged on oral agents for social reasons. Eighteen different antibiotics were used. The most common single agents were amoxycillin (four patients) and ciprofloxacin (four patients) and the most common combinations were flucloxacillin/amoxycillin, fusidic acid/rifampicin, rifampicin/erythromycin, rifampicin/trimethoprim, vancomycin/gentamicin and vancomycin/ rifampicin, each for two patients. Of 50 patients considered cured by teicoplanin, 18 were given subsequent antibiotics compared with 29 of 54 patients who failed teicoplanin treatment (NS, y} test).
The most common pathogens were Streptococcus sanguis, S. aureus and Staphylococcus epidermidis (Table V) . Most were isolated from the blood (79/104, 76%) but two were from a cardiac valve and two were suspected from serology. There was no significant difference in cure rates of disease caused by staphylococci and that caused by streptococci. As expected, a-haemolytic streptococci were more common in native valve infections than in prosthetic infections (31/58 vs. 9/46, x l = \\, P < 0.001) but there was no significant difference in the proportion of cases caused by CoNS (6/58 vs. 11/46, NS) . No pathogen was isolated in 20 patients.
Various methods were used to measure MICs including broth dilution (27 cases), microtitre plates (19 cases), plate methods (three cases) and Etest (two cases). . Maximum bactericidal dilution of serum varied from 2 to 1024 but there was no significant difference between the titres in patients who were cured and those who failed (median both groups 8; NS, Mann Whitney test).
Serum assays were performed in 46 patients but the proportion of patients depended on the hospital. Guy's, Royal London and North Middlesex assayed all patients and Edgware and East Surrey assayed the majority. University College performed assays in 56% of 39 patients but the Royal Brompton and the London Chest Hospitals assayed only a minority. Median trough serum concentrations were of 19 mg/L (7.3-117 g/L) and the median peak was 40 mg/L (18-137 mg/L, 33 patients) For trough concentrations over 20 mg/L (n = 19), there were two cures in five cases caused by S. aureus and three cures in ten cases caused by other pathogens (pathogen not known in five patients). For concentrations less than 20 mg/L (n = 27), there was one cure in three infections caused by S. aureus and 13 in 24 cases caused by other organisms (one case culture-negative).
There were 27 deaths (26%), half of them directly due to infection. In seven of the remainder, infection may have been contributory: two died from intracerebral bleeds, two from coronary emboli and three from cardiac failure. Other patients died as the result of AIDS (1), leukaemia (1), gastrointestinal bleeding (1), elective cardiac surgery after recovery (2) or unrelated causes (3). Fourteen of the deaths occurred during the hospital stay and the rest between 24 and 633 days after discharge, seven being more than 6 months after recovery. More patients with prosthetic valve endocarditis died than did with native valve endocarditis (17/46 vs 9/58, f = 5, P < 0.025) although resort to surgery was similar in both groups (22/46 vs 29/58, NS). Follow-up was for a median of 429 days, for 16 being less than 6 months of which seven were less than 1 month.
Of 80 patients febrile at the start of treatment with teicoplanin, 63 (79%) lost their fever within a median of 2 days (1-35 days), the fever recurred after a brief response in two, and in 15 (19%) the fever did not respond. In the remaining 24 patients, fever had been lost prior to teicoplanin treatment, the change being determined by adverse reactions or in-vitro susceptibility. During treatment, valvular leakage developed in nine patients, cardiac failure in 25 (24%), emboli in 11, root abscess in 15 (14%), mycotic aneurysm in three and other complications in five. Serial blood cultures were taken in 21 patients and became negative a median of 4 days into treatment (range 1-14 days). In ten patients, blood cultures remained positive and in 46 patients they were initially negative usually because they were taken during previous antibiotic treatment. Surgery was performed in 52 (50%) patients, usually because of a valvular leak (14 patients, five of whom had leaks before teicoplanin treatment was started), cardiac failure (12 patients) or persistent fever (12 patients). Seven patients had surgery for an abscess and three because the size of the vegetation was increasing. The median delay from admission to surgery was 30 days (range 1-444).
Clinical cure of native valve endocarditis by medical treatment alone was achieved in 28 (48%), medical treatment failed in 29 and outcome was indeterminate in one. Of the failures, treatment was stopped early in two patients because of adverse events and in another four surgery was performed during treatment despite the patient having become afebrile. Of prosthetic valve endocarditis, medical treatment cured 22 (48%) and failed in 24 of whom one had an adverse event and one had surgery despite being afebrile. Cure rates were similar for aortic and mitral valves (18/48, 20/41). Most patients (86%) were treated in tertiary referral centres with access to cardiac surgery, and of these 41 (46%) were cured. Fifteen patients were treated in district general hospitals, and of these nine (60%) were cured. By causative pathogen, medical treatment cured five often cases with S. epidermidis, six of 13 S. aureus, two of five S. bovis, three of five S. mitis, and six of 11 5. sanguis. A bacteriological outcome was not evaluable in 24 patients. Of the remainder, proven bacteriological cure was achieved in 22 (27%) but clinical signs persisted in 11 of these; 39 (47%) had a presumptive bacteriological cure, and bacteriological failure or persistence occurred in 19 patients (23%).
Cure rates of endocarditis on native or metal valves for teicoplanin were similar if no replacement were needed (Table VI) . Most who required replacement were considered to have failed treatment with teicoplanin but 78% survived regardless of the type of valve at presentation. There was no significant difference in the proportion of infected metal or xenograft prosthetic valves replaced. The most common replacement valves were metal.
Adverse events occured in 45 patients (Table VII) of which the relationship to teicoplanin was thought probable in 14. Teicoplanin was stopped in 20 cases and other action taken to address the cause in five cases. Three patients died as a result of the adverse event but no deaths were thought likely to be related to teicoplanin. One patient suffered a coronary embolus, one a gastrointestinal haemorrhage and one an intracranial bleed. All other events resolved although some had a prolonged course. One case of vertigo and two of renal failure were thought more likely to be related to 
Discussion
Teicoplanin combined with other antibiotics was sufficient to achieve cure without surgery in 48% of evaluable patients treated for endocarditis, regardless of the presence of valvular prostheses. Most patients had already been referred to tertiary hospitals for possible cardiac surgery and had severe disease against which medical treatment had already failed. Of those patients febrile at the start of teicoplanin treatment, 79% became afebrile within a median of two days. A total of 75% of patients survived, those with native valve endocarditis having the better outcome. Most deaths were directly or indirectly the result of active infection. Teicoplanin was stopped because of adverse events in 19% of cases but only 13% were thought to be probably related to teicoplanin. Serum creatinine was not significantly affected by treatment with teicoplanin. Teicoplanin has several properties that suggest that it would be useful in endocarditis. It is active against most Gram-positive bacteria, it is administered once daily and it has a high therapeutic index. Uncontrolled trials have indicated that teicoplanin was effective in this condition. Lewis et al. (1988) reported cures in 58 of 83 patients given 200-400 mg daily, 38 of whom were treated with teicoplanin alone and 30 (79%) of these were cured (Davey & Williams, 1991a) . Patients cured following surgery without change in antibiotics were counted as cures. In the present study, most patients had combination therapy and ten patients who survived following surgery with no change in antibiotics were defined as failures, according to the recent, stringent European criteria (Wilson et al., 1993) . If Davey & Williams (1991 a) criteria were applied, the cure 
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O *-< a "Single patients developed the following: abdominal pain, bowel obstruction, gastrointestinal haemorrhage, vertigo, paraesthesia, intracranial bleed, retinal detachment, visual disturbance, coronary embolus, embolus to leg and leucopenia; each thought possibly or unlikely to be related to teicoplanin. rate in this study would be 58%. Of 23 episodes of endocarditis treated by Martino et al. (1989) , four required other antibiotics, four valve replacement and one both. Cure was achieved in 21 of 23 patients, including nine with staphylococcal disease, using a dose of 3-7 mg/kg/day, increased to achieve adequate bactericidal activity. In another study, 20 patients were given a mean dose of 7 mg/kg/day, usually in combination. Three stopped treatment following adverse effects but 14 of the 17 were cured (Leport et al., 1989) . Using 600 mg/day of teicoplanin alone, Presterl et al. (1993) reported cures in 24 of 26 patients although ten required surgery. A 4-week course of 10 mg/kg/day has been found to be effective in native valve streptococcal endocarditis (Venditti et al., 1992) . One patient died, four were excluded and five developed drug fever. Of ten completing treatment, nine were cured.
However, some trials have been less successful. Glupczynski et al. (1986) used a low daily dose of 200 mg teicoplanin as monotherapy and apparently without a loading regimen, and found that four of seven patients failed treatment. Most failures were caused by susceptible S. aureus. Three of five patients were not cured at a mean dose of 7.8 mg/kg in another study (Fernandez-Guerrero et al., 1990) . In a randomized double blind US trial, there were five failures in eight patients given teicoplanin (6 mg/kg/day) compared with one failure in six given vancomycin (Gilbert et al., 1991) . The failures were again caused by S. aureus. The trial was stopped before statistical significance was reached. Higher doses were then used to maintain a trough concentration of 25 mg/L but the final unpublished results still suggested teicoplanin was less effective than vancomycin (3/14 vs 5/6, P = 0.04) . Another open US study raised protocol doses from 6 mg/kg/day to an eventual 15 mg/kg every 12 h for S. aureus endocarditis and 6-15 mg/kg/day for streptococcal endocarditis . Between a third and a half of patients were given other antibiotics. Clinical success was obtained in 20 of 31 patients, a trough serum concentration of 20 mg/L appearing to be the important factor (<20 mg/L 4/10 cures, >20 mg/L 10/11 cures).
Finally a randomised double-blind US trial reported the results of treatment with doses intended to achieve teicoplanin trough concentrations of 40-60 mg/L for S. aureus disease (30 mg/kg, 24 h) or 6 mg/kg/day for streptococcal disease . There were 16 cures in 21 patients compared with 26 of 34 given vancomycin (no significant difference). Staphylococcal disease was eradicated in nine of 13 patients. The definition of success did not include avoidance of surgery. Current recommendations are for a maintenance dose of 12 mg/kg/day to keep trough levels over 20 mg/L (or a lower dose if used in combination) for S. aureus endocarditis and 6 mg/kg/day for endocarditis caused by other pathogens .
In the present study, trough concentrations were around 20 mg/L in more than half the patients having assays but there was no agreement on when to assay. There was no obvious dose relationship between the trough level and success in S. aureus endocarditis but numbers were small and combination treatment was used in most. Except at doses over 12 mg/kg/day, monitoring is not necessary to avoid toxicity but is needed to ensure adequate therapeutic levels in those not responding to treatment, in the intravenous drug abuser in whom clearance is erratic, or in patients with renal failure (Rybak et al., 1991; . A single assay at the steady state is sufficient, unless renal function changes, to ensure a minimum trough of 15 mg/L (or 20 mg/L in monotherapy of staphylococcal endocarditis) . Loading doses were not used in a quarter of the patients in this survey even though this would delay steady state levels by up to one week (Carver et al., 1989) . Higher doses were used in some of the patients treated for infection with S. aureus but the 6 mg/kg dose was usually given whatever the cause.
Microbiological assay was used to determine serum concentrations but this requires an overnight incubation and is prone to interference. Other methods for teicoplanin include solid phase enzyme receptor assay (SPERA), receptor antibody sandwich assay (RASA), fluorescence polarisation immunoassay (FPIA) and high performance liquid chromatography (HPLC) (Cavenaghi, Corti & Cassani, 1987; Rowland, 1990) . The usual method is the FPIA, which is a competitive binding immunoassay using fluorescein-labelled antigen for which the limit of detection is 1 mg/L and the coefficient of variation is less than 10% from day to day. It is rapid and quick to perform but expensive. A recent quality control assessment of European laboratories showed only 61% results returned were satisfactory (White et al., 1996) . Only one of three laboratories using plate assay and two of five using HPLC produced adequate results compared with 12 of 14 using FPIA.
Our mortality rate of 26% is similar to that reported by others for staphylococcal endocardites (26%) or for death in hospital from all types of endocarditis (28%) (Watanakunakorn, 1994; Wells et al., 1990) , There was no significant difference in success rates between staphylococcal and streptococcal infections. Half the patients required surgery for complications, which were usually the result of infection. Under the criteria used these are deemed failures. However, most patients had already failed medical treatment elsewhere and some complications preceded the use of teicoplanin. The mortality from prosthetic valve endocarditis treated by antibiotics alone (56%) is known to be significantly higher than in patients having both medical and surgical treatment (Yu et al., 1994) . The need for replacement seemed to be similar for endocarditis on metal and xenograft valves. The use of oral antibiotics, after completion of teicoplanin treatment, was common practice even in patients thought to have recovered, in an attempt to prevent recrudescence of fever.
Resistance to teicoplanin was rare but enterococci, and some staphylococci and a-haemolytic streptococci were inhibited but not killed by teicoplanin. There was no significant relationship between MIC and cure, confirming earlier findings in a range of infections (Harding & Garaud, 1988) . For pathogens with an MIC of 8 mg/L or more, three of six episodes were cured (in two strains a range of MICs was observed). However, there was a trend to fewer cures of infections caused by pathogens with an MBC of 8 mg/L or more.
Teicoplanin was used successfully for home treatment in 12 patients, two of whom had S. aureus endocarditis. Presterl et al. (1993) treated a third of 26 patients at home with teicoplanin after a 2-week hospital stay. The choice of intravenous or intramuscular routes, the once daily dosage, low toxicity and lack of need for routine monitoring favour the use of teicoplanin over vancomycin for home treatment . With the increasing costs of hospitalisation, it is likely that this form of treatment will increase for selected patients, particularly those with well-controlled streptococcal disease.
Adverse events were generally minor and effects were thought to be related to teicoplanin in only 13% of patients. Treatment was changed due to adverse events in 19% of episodes. Five patients developed renal failure but fever (7) and rash (6) were slightly more common. In a safety database of 3377 patients treated for various infections, only 2.6% showed hypersensitivity and 0.6% altered renal function (Davey & Williams, 19916) . However, in the prolonged high dose courses ssometimes used in endocarditis and osteomyelitis, a higher incidence of effects would be expected. Unpublished US trials suggest both fever and rigors are dose dependent . In a double-blind randomised trial of treatment of endocarditis using high doses, rash and fever occurred in ten of 147 patients given teicoplanin compared with 6 with fever and 7 with rash of 146 given vancomycin. Nephrotoxicity was observed in four patients in each group and thrombocytopenia occurred in seven patients given teicoplanin versus one given vancomycin. Thrombocytopenia has previously been associated with the use of very high doses of teicoplanin . In the present study, it developed in three patients leading to the withdrawal of teicoplanin in two. Presterl et al. (1993) noted a rise in bilirubin in four of 26 patients compared with two of 104 in this study.
In animal models, nephrotoxicity is dose-dependent and is observed with similar doses in both vancomycin and teicoplanin. However, lower doses of teicoplanin are used in practice and nephrotoxicity is infrequent. Vancomycin would be expected to induce a 50% increase in serum creatinine above baseline in 5% of patients if given alone or in 22% if given with an aminoglycoside (Rybak et al., 1990) . Creatinine did not change significantly following treatment with teicoplanin in the present study, and only five patients developed renal failure.
This study was retrospective and serves only as a record of recent UK practice in the prescription of teicoplanin for the treatment of endocarditis. A multi-centre randomized trial is the only basis from which to draw firm recommendations but the practical difficulties in mounting such a trial are considerable. The patient population in the present study had already been referred from local hospitals because of difficulties in management and prognosis would not be expected to be good. Nevertheless, a high proportion became afebrile on treatment and survived following surgery. Teicoplanin appeared to be safe and should be considered for the home treatment of susceptible infections.
